Zhongyuan Concord: The clinical trial application for the full subsidiary VUM02 injection has been accepted.

date
04/08/2025
Zhongyuan Co., Ltd. announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., obtained the "Acceptance Notification Letter" issued by the National Medical Products Administration Drug Evaluation Center on August 1, 2025 for the clinical trial application of VUM02 injection. VUM02 injection is a frozen storage cell preparation independently developed by Zhongyuan Co., Ltd., and the clinical indication is for the treatment of lung fibrosis after pneumonia. As of June 2025, the cumulative research and development investment for the project is RMB 22,330,000. According to China's drug registration laws and regulations, after the clinical trial application is accepted, if there are no negative or questioning opinions from the National Medical Products Administration Drug Evaluation Center within 60 working days from the acceptance date, the clinical trial can be conducted according to the submitted plan.